TENX

Business Context and Reporting Period

Company: Synthetic Blood International, Inc. (Note: Metadata referenced "Tenax Therapeutics," but the filing text identifies the registrant as Synthetic Blood International, Inc.)
Reporting Period: Quarterly period ended July 31, 2006.
Status: Development stage company focused on perfluorocarbon-based medical products, primarily "Oxycyte" (a synthetic blood substitute) and "Fluorovent" (an oxygen exchange fluid). The company is in pre-clinical and clinical trial stages with no commercial revenue.

Key Financial Metrics

Cash Flow Summary (Three Months Ended July 31, 2006):
- Operating Activities: $(235,166)
- Investing Activities: $(5,607)
- Financing Activities: $248,090 (Primarily proceeds from short-term notes payable)

Material Changes vs. Prior Period

• Liquidity Crisis: Cash and cash equivalents plummeted from $1,281,423 in July 2005 to $7,699 in July 2006. The company now has negative working capital of $613,442.
• Increased Losses: Net loss increased by approximately $98,722 (16%) compared to the prior year quarter, driven primarily by a $220,003 increase in interest expense due to new debt and amortization of debt discounts.
• Expense Shifts: Research and Development (R&D) expenses decreased by $109,993 to $230,180, largely due to reduced Phase II clinical trial activity. General and Administrative (G&A) expenses increased slightly to $284,510 due to higher consulting fees, partially offset by lower legal fees.
• Debt Structure: Significant increase in current liabilities, including notes payable and convertible debentures, to fund operations.

Outlook, Risks, and Management Commentary

• Going Concern Doubt: Management explicitly states that the company lacks the working capital to fund operations for fiscal year 2007. There is substantial doubt about the company's ability to continue as a going concern without immediate additional financing.
• Financing Needs: The company estimates an additional $8,000,000 is required to complete Phase II clinical trials for Oxycyte in 2006 and 2007. Management is actively seeking equity or debt financing but offers no assurance of success.
• Clinical Trial Status:
  • Oxycyte (Hip Surgery): Enrollment temporarily halted due to slower-than-expected patient recruitment (12 patients enrolled vs. higher expectations).
  • Oxycyte (Sickle Cell Anemia): Placed on clinical hold by the FDA pending protocol changes.
  • Oxycyte (Brain Ischemia): Completed an 8-patient proof of concept study.
• Other Products: Development of Fluorovent and the glucose biosensor implant is ongoing but not expected to reach FDA filing for at least two years.
• Accounting Changes: The company adopted SFAS No. 123(R) regarding share-based payment effective May 1, 2006, resulting in the recognition of approximately $14,000 in non-cash stock-based compensation costs for the quarter.

Investor Verification Checklist

• Immediate Liquidity: Verify if the company has secured the immediate financing required to cover administrative expenses and avoid ceasing operations.
• Debt Covenants: Review terms of the new notes payable and convertible debentures for interest rates (up to 18%), maturity dates, and potential dilution from warrant exercises.
• Clinical Trial Resumption: Confirm the status of the FDA hold on the sickle cell anemia trial and the timeline for restarting the hip surgery trial enrollment.
• Related Party Transactions: Note the $60,000 loan from an officer and payments to a manufacturer where an officer is a minority shareholder.
• Going Concern Opinion: Review the independent auditor's report for the explanatory paragraph regarding the uncertainty of the company's ability to continue as a going concern.